Self expanding stents for the management of aorto-ostial stenoses in saphenous vein bypass grafts

Jan-Eric Nordrehaug, Kim A Priestley, Nicolas A F Chronos, Anthony F Rickards, Nigel P Buller, Ulrich Sigwart

Abstract

Objective—To assess the early and follow up results of implantation of a self expanding stent in aorto-ostial stenoses of vein grafts.

Design—Prospective, non-randomised, observational study.

Setting—Tertiary referral centre for cardiac diseases.

Patients—Nineteen patients with ostial stenoses of saphenous vein grafts.

Main outcome measures and results—Stents were successfully deployed in all 19 patients with satisfactory angiographic results. In one patient this required two attempts. There were no deaths and no major procedural complications related to ostial stenting. Before discharge two (11%) patients had thrombosis of the ostial stent; one patient had a Q wave myocardial infarction. Femoral artery bleeding occurred in three (16%) patients. Angiographic follow up was performed in 18 patients at a mean of seven months. Restenosis within the ostial stent was detected in three (16%) patients. Twelve (63%) patients had an improved functional status at a mean follow up of nine months. One patient died suddenly at three months. Three (16%) patients required additional revascularisation procedures because of symptoms caused by restenosis within the ostial stent during follow up.

Conclusions—Intracoronary stenting is an attractive treatment for the management of patients with vein graft ostial stenoses.

Conventional balloon angioplasty of aorto-ostial lesions often produces a suboptimal angiographic result and has a higher risk of procedural complications and restenosis than angioplasty of non-ostial lesions. Indeed, in the major multicentre trial in the USA, balloon angioplasty for right coronary artery ostial stenosis was unsuccessful in 11 (21%) of 53 patients, of whom five (9%) required emergency coronary artery bypass grafting because of abrupt closure. Angina subsequently recurred in 20 (48%) of the 42 patients with an initially successful outcome after a mean follow up of 12.5 months. Sixteen (38%) of these 42 patients had repeat angiography which confirmed restenosis. Balloon angioplasty of ostial lesions in saphenous vein grafts has an even higher restenosis rate; 79% in one series. In view of these poor results several alternatives or adjuncts to conventional angioplasty have been investigated for the treatment of aorto-ostial lesions. Directional coronary atherectomy and excimer laser angioplasty are reported to have a higher primary success rate than balloon angioplasty, but the restenosis rates are similar. We report the initial and follow up results of the implantation of a self expanding stent in patients with aorto-ostial stenoses in bypass grafts.

Patients and methods

Nineteen patients were implanted with a self expanding stent (Wallstent, Medinvent SA, Lausanne, Switzerland) in the ostium of a saphenous vein graft. Table 1 summarises the clinical characteristics of the patients. All patients had a significant stenosis (≥ 70%) within 3 mm of the ostium of the graft. The mean diameter of the stenosis was 87 (7%) before intervention, as assessed by caliper measurements in standard orthogonal views. The vein graft supplied the left anterior descending artery in seven patients, the circumflex artery in six, and the right coronary artery in six. The target lesion was a restenosis in five (26%) patients.

PROCEDURE

All patients gave informed consent to stent insertion and a standard procedure for implantation of the self expanding stent was followed. The ostial lesion was predilated

Table 1  Clinical characteristics of patients

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (mean (SD))</td>
<td>60 (9) yr</td>
</tr>
<tr>
<td>Sex Ratio (male:female)</td>
<td>10:4</td>
</tr>
<tr>
<td>Angina (NYHA):</td>
<td></td>
</tr>
<tr>
<td>Grade 1</td>
<td>2</td>
</tr>
<tr>
<td>Grade 2</td>
<td></td>
</tr>
<tr>
<td>Grade 3</td>
<td>11</td>
</tr>
<tr>
<td>Grade 4</td>
<td>6</td>
</tr>
<tr>
<td>Previous myocardial infarction</td>
<td>11 (58%)</td>
</tr>
<tr>
<td>Ejection fraction (mean (SD))</td>
<td>57 (12)%</td>
</tr>
</tbody>
</table>

NYHA, New York Heart Association.
using an angioplasty balloon catheter and the special stent delivery system advanced over the angioplasty guide wire via an 8 Fr guide catheter. Correct positioning of the stent was facilitated by markers at its proximal and distal ends. The constraining membrane was partially retracted to allow expansion of the distal end of the stent, thus anchoring the stent in position. The guide catheter was pulled back into the aorta and the stent allowed to expand fully by manipulation of the delivery catheter. Further balloon inflations within the stent were often required to obtain a satisfactory angiographic result.

Sixteen (84%) patients had additional interventions at the same procedure. Conventional balloon angioplasty of a second lesion was performed in 12 (63%) patients, one patient had two adjacent stents, and three patients had a second stent in another location.

ANTITHROMBOTIC DRUG REGIMEN
Aspirin (150–300 mg) was started the day before the procedure and continued indefinitely. Warfarin and dipyridamole were started at the same time and continued for three months. Dextran 40 was given intravenously during the procedure and continued over the next three to five hours (500 ml total). Intra-arterial heparin (15 000 IU) was administered at the start of the procedure with additional boluses each hour to keep the activated clotting time greater than 300 seconds. Heparin was continued on the ward until effective anticoagulation with warfarin was established (international normalised ratio 2.5–3.5).

STATISTICAL ANALYSIS
Values are expressed as mean (standard deviation (SD)).

Results

EARLY RESULTS
A stent was successfully deployed in the ostial lesion in all 19 patients. The mean diameter stenosis was 51 (20%) after balloon predilatation and this was reduced by stent implantation to less than 20% in all patients. In one patient the initial stent could not be accurately deployed. It was retracted back into the aorta and subsequently deployed in the right iliac artery without any adverse effects. A second stent was successfully placed in the ostial lesion. The mean unconstrained stent diameter used was 4.9 (1.0) mm (range 3.0–6.0) and the stent length was 27 (5) mm (range 15–40).

Table 2 gives procedural and in-hospital complications related to the ostial stent. In addition, one patient had thrombosis of a second stent placed in a non-ostial location. This patient had a Q wave myocardial infarction despite intracoronary thrombolysis and repeat angioplasty. A second patient had a non-Q wave myocardial infarction after abrupt closure of a balloon angioplasty site. The vessel was reopened and a stent implanted with an excellent angiographic result.

<table>
<thead>
<tr>
<th>Complication</th>
<th>No (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Death</td>
<td>0</td>
</tr>
<tr>
<td>Emergency coronary operation</td>
<td>0</td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>1 (5) (non-Q wave)</td>
</tr>
<tr>
<td>Stent thrombosis</td>
<td>2 (11)*</td>
</tr>
<tr>
<td>Femoral artery bleeding</td>
<td>3 (16)*</td>
</tr>
</tbody>
</table>

*One patient had a Q wave myocardial infarction.

Three (16%) patients had femoral artery bleeding; all three required an operation for repair.

FOLLOW UP
Follow up angiograms were obtained in all 18 eligible patients (95% angiographic follow up); one patient died before the planned follow up angiography. Angiography was performed early in one patient because of symptoms (four months). In the remaining patients angiography was performed after a mean of seven months (range 5–18 months).

Table 3 gives the results. Restenosis within the ostial stent, defined as ≥50% diameter reduction, was detected in three (17%) patients.

The mean clinical follow up was nine (three) months; the results are shown in table 4. Twelve (63%) patients had an improved functional status at follow up; indeed, 10 (53%) patients were asymptomatic. One patient died suddenly at three months. He had had a thrombosis of a non-ostial stent, resulting in a Q wave myocardial infarction, while in hospital. Necropsy results were not available.

Three (16%) patients required repeat angioplasty because of symptoms due to restenosis within the ostial stent during follow up. A further four patients required additional revascularisation procedures because of restenosis after balloon angioplasty at a second site, or because of new disease.

Discussion

The results of conventional balloon angioplasty of aorto-ostial lesions are often disappointing. Typically, the lesions are difficult to dilate and require high pressure inflations. In a series of 53 patients with right
Self-expanding stents in aorto-ostial stenoses

Coronary ostial stenoses have a mean diameter stenosis of 33.5% (26%) after balloon angioplasty and procedural success was achieved in 79% of patients. In comparison, laser angioplasty of ostial stenoses has a reported procedural success of 96% and directional coronary atherectomy of between 78% and 86%. In our series of 19 patients with ostial lesions in vein grafts the mean diameter stenosis after balloon predilation was 51% (20%). The implantation of a stent produced an excellent angiographic result in all patients, although one patient required a second attempt. Stent deployment in the ostium of vein grafts thus has a similar level of success to stent deployment in other locations in native coronary arteries and bypass grafts.

The flexibility of the self-expanding stent and the availability of a variety of lengths make it particularly well suited for use in aorto-ostial lesions and vein grafts. Its precise positioning in the ostial location, however, requires considerable expertise. The self-expanding feature implies that significant shortening of the stent occurs on delivery. As the distal portion of the stent is deployed first the proximal end will move into the target vessel until an equilibrium is reached between radial expansion and lesion compliance. This factor must be considered when positioning the distal end of the stent. If incorrectly positioned the proximal end of the stent may protrude into the aorta or not cover the lesion completely. Protrusion of the stent into the aorta could theoretically provide a nidus for thrombus formation. This has not been realised in clinical practice. None of our patients had any overt thromboembolic phenomenon.

Procedural complications are high after balloon dilation of aorto-ostial lesions, with up to 10% of patients needing an emergency coronary operation. An emergency operation was required in between 0% and 4.9% of patients with ostial lesions after directional atherectomy and in 2.6% after excimer laser angioplasty. There was no major procedural complication in our patients. Thrombosis of the ostial stent, however, occurred in two (11%) patients. In one patient stent thrombosis occurred after premature discontinuation of anticoagulation drugs, but in the other patient the strict anticoagulation regimen was adhered to. In the two patients the stent was dislodged by intracoronary thrombolytics and repeat angioplasty; one patient sustained a Q wave myocardial infarction. Stent thrombosis is a concern and published studies suggest that the self-expanding stent may have a higher thrombotic tendency than other stent designs.

The incidence of bleeding complications is similar in all stent studies and relates to the intensive anticoagulation and regimen required. It is hoped that femoral bleeding, which occurred in 16.7% of patients in our series, will be reduced by new devices and techniques for securing femoral haemostasis.

A 17% restenosis rate is lower than that reported for aorto-ostial lesions treated by conventional balloon angioplasty (48–79%), atherectomy (14–60%), or laser (47%) angioplasty. The restenosis rate is particularly low considering that the stents were placed in the ostial location of vein grafts, a site with a high prevalence of proximal restenosis and occlusion for restenosis after balloon angioplasty (79%). Several factors may contribute to this low restenosis rate. In particular, lower restenosis rates are associated with de novo lesions (74% in our series), a residual stenosis of <20% after stenting (achieved in all our patients), and large stent diameter (mean 4.9 mm in our series, smallest 3 mm).

In conclusion, the morbidity and mortality associated with a repeat coronary operation make stenting an attractive treatment in patients with vein graft ostial stenoses. In this series the self-expanding stent was associated with a high angiographic success rate, low procedural complications, and a low risk of restenosis. Stent thrombosis and femoral artery bleeding were significant problems, but these may be reduced with newer stent designs and devices for securing femoral haemostasis. Randomised studies comparing the results of stenting of aorto-ostial lesions in saphenous vein grafts with those of directional atherectomy and excimer laser are urgently needed.